Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Jennifer G. Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S.G. Stroes; Gisle Langslet; Frederick J. Raal; Mahfouz El Shahawy; Michael J. Koren; Norman E. Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J.P. Kastelein

doi:10.1056/nejmoa1501031

Abstract

Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).

Keywords

AlirocumabMedicineInternal medicineCholesterolLipoprotein

Affiliated Institutions

Related Publications

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Gregory G. Schwartz , Philippe Gabríel Steg , Michael Szarek +19 more

Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower am...

2018 New England Journal of Medicine 3201 citations

Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study

Peter H. Jones , John A. Farmer , Michael D. Cressman +12 more

Abstract This multicenter, double‐blind, placebo‐controlled study was conducted to evaluate dose‐response effects and safety of once‐daily administration of pravastatin, a new i...

1991 Clinical Cardiology 65 citations

Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])

Harold Bays , Carlos A. Dujovne , Mark E. McGovern +4 more

This study compared the relative efficacy of a once-daily niacin extended-release (ER)/lovastatin fixed-dose combination with standard doses of atorvastatin or simvastatin, with...

2003 The American Journal of Cardiology 153 citations

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)

Peter H. Jones , Michael H. Davidson , Evan A. Stein +5 more

The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin acros...

2003 The American Journal of Cardiology 1382 citations

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical b...

2011 New England Journal of Medicine 2850 citations

Publication Info

Year: 2015
Type: article
Volume: 372
Issue: 16
Pages: 1489-1499
Citations: 2233
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2233

OpenAlex

Cite This

APA Style

                            
                                
                                    Jennifer G. Robinson, 
                                
                                    Michel Farnier, 
                                
                                    Michel Krempf
                                
                                et al.
                            
                            (2015). 
                            Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. 
                            New England Journal of Medicine
                            , 372
                            (16)
                            , 1489-1499.
                            https://doi.org/10.1056/nejmoa1501031
                        

Identifiers

DOI: 10.1056/nejmoa1501031